Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Pleural Diseases 2Pancreatic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Non-Muscle Invasive Bladder Neoplasms 1Mesothelioma, Malignant 1Glioma 1Glioblastoma 1Epitheliod Malignant Pleural Mesothelioma 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Basal Cell 1

Interventions

Nivolumab 7cemiplimab 6Specimen Handling 5HhAntag691 5Radiotherapy 4Magnetic Resonance Spectroscopy 4Ipilimumab 4Biopsy 4sonidegib 3pembrolizumab 3CTLA-4 Antigen 3relatlimab 2prednylidene 2deltacortene 2daromun 2Surgical Procedures, Operative 2Standard of Care 2Prednisone 2Observation 2Aminolevulinic Acid 2tocilizumab 1talimogene laherparepvec 1poly ICLC 1flt3 ligand protein 1X-Rays 1Watchful Waiting 1Vitamin D 1Tomography, Optical Coherence 1Therapeutics 1Tacrolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Basal Cell × 1-phenyl-3,3-dimethyltriazene × 1 year × Clear all
NCT05020912 2026-06-01

Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy

Case Comprehensive Cancer Center

Phase 2 Active not recruiting
18 enrolled
Dermatologic

Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡